ArticleJournal of cachexia, sarcopenia and muscle2024
Association of low muscle mass and obesity with increased all-cause and cardiovascular disease mortality in US adults.
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Sarcopenic obesity and risk of cardio-cerebrovascular disease and mortality: a systematic review and meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Trial
- Aging-, obesity-, and diabetes-related sarcopenia: Pathogenesis and interventions.Chinese medical journal · 2026Review
- Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice.Journal of endocrinological investigation · 2026Article
- Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- The mediating role of healthy lifestyle in the association between higher socioeconomic status and an increased risk of allergic rhinitis: an analysis of NHANES.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery disease.American heart journal plus : cardiology research and practice · 2026Article
- Association between sarcopenia and mortality in patients with osteoarthritis.Clinical rheumatology · 2026Article
- Sarcopenic obesity and body composition phenotypes in older adults with chronic kidney disease: associations with estimated mortality risk.Scientific reports · 2026Article
- Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.International journal of obesity (2005) · 2026Article
- Muscle Mass Moderates Metabolic Syndrome Risk Associated with Adiposity: A SHAP-Based Machine Learning Study.Nutrients · 2026Article
- Sarcopenic obesity definitions and their association with cardiovascular disease and mortality.BMC geriatrics · 2026Article
- Unraveling functional decline: the relationship between muscle strength and ultrasound evaluation of biceps brachii thickness.GeroScience · 2026Article
- Handgrip Strength and Trajectories of Preclinical Obesity Progression: A Multistate Model Analysis Using the UK Biobank.The Journal of clinical endocrinology and metabolism · 2026Article
- Muscle mass as a resilence factor for endothelial health in obesity.npj metabolic health and disease · 2026Review
- Obesity Reprogrammes Adipose Extracellular Vesicles to Induce Muscle Atrophy via miR-150-5p-Mediated Transcriptional Silencing.Journal of cachexia, sarcopenia and muscle · 2026Article
- Association of skeletal muscle index and intermuscular adipose tissue index measured by non-contrast chest CT with major adverse cardiovascular events in patients with coronary artery disease: a nested case-control study in a Chinese population.Frontiers in cardiovascular medicine · 2026Article
- Erector spinae density as a predictor of early cardiac complications in patients with stroke.Frontiers in cardiovascular medicine · 2026Article
- Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026Review
- Joint association of low muscle mass and mild anemia with all-cause, cardiovascular and cancer mortality among US middle and older adults.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSarcopenic obesity, defined as the coexistence of low muscle mass and high adiposity, is associated with cardiovascular disease (CVD) and mortality. However, to what extent sarcopenia contributes to these risks independently or in conjunction with other cardiovascular risk factors remains unclear. This study aimed to investigate the association of low muscle mass, central obesity (COB), metabolic abnormalities, and their combinations with CVD and mortality risk.
methodsThis cross-sectional analysis used data from the National Health and Nutrition Examination Survey 1999-2006 and 2011-2018. Participants aged >20 years and with reported whole-body dual X-ray absorptiometry data were included. Participants were divided into eight groups based on low muscle mass, metabolic abnormalities, and COB status.
resultsThe mean age of participants was 55 years, and 50.4% of participants were male. Low muscle mass was observed in 2472 (14.6%) out of 16 839 participants. Among the eight groups, the metabolically unhealthy COB group with low muscle mass had the highest hazard ratio (HR) for all-cause mortality (HR, 2.00; 95% CI, 1.56-2.56; P < 0.001), whereas the metabolically healthy COB group with low muscle mass had the highest HR for CVD mortality (HR, 3.18; 95% CI, 1.53-6.65; P = 0.001). The mediation analysis showed that low muscle mass directly increased the risk of both all-cause mortality (HR, 1.56; 95% CI, 1.35-1.79; P < 0.001) and CVD mortality (HR, 1.80; 95% CI, 1.40-2.31; P < 0.001). Additionally, subgroup analysis revealed that low muscle mass significantly increased the risk of all-cause and CVD mortality in participants without a prior CVD history and those with diabetes mellitus.
conclusionsLow muscle mass is an independent risk factor for all-cause and CVD mortality, especially in individuals with metabolic abnormalities and COB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.